Oncology

A new bispecific antibody, TRIV-573, enters clinical trials, targeting both skin barrier and inflammation to redefine atopic dermatitis therapy.

The biotech firm raises cash via a complex warrant deal, diluting shares to fund its promising but challenging RNAi therapy for deadly KRAS-driven cancers.

The Nexus Forum launches to connect China's booming biotech scene with global pharma, capitalizing on a major shift in worldwide drug discovery and deal-making.

A new pill-only combination drug for acute myeloid leukemia promises to reduce hospital visits and improve quality of life for elderly and unfit patients.

With strong HIFU revenue and new clinical trials, EDAP TMS's upcoming Investor Day will reveal its strategy for medtech dominance and investor confidence.

University of Michigan Health is the first in the Midwest to use Unfold AI, a new platform creating 3D cancer maps to personalize patient treatment.

Pharma and COVID-response leader John Young joins UCSF's QBI to translate its cutting-edge protein science into transformative therapies and partnerships.

Arvinas secures a historic first FDA approval for a PROTAC drug and inks a deal to fuel a deep pipeline targeting cancer and neurodegenerative diseases.

Anaveon reveals promising ASCO data for its cancer drug ANV600, yet puts the asset on the market to fund a bold new focus on autoimmune diseases.

An innovative RNA-editing therapy for hepatocellular carcinoma has received a major FDA designation, potentially accelerating its path to patients.

Artivion posts strong Q1 results and acquires Endospan for its FDA-approved NEXUS system, yet lowers its full-year guidance. What's behind the mixed message?

The Italian pharma giant appoints a global health policy heavyweight, signaling a strategic pivot towards tackling complex global challenges and a new era.

With key clinical data on the horizon for its cancer and ALS drugs, LeonaBio adds deep financial, operational, and strategic expertise to its leadership.

Vancouver's ME Therapeutics will unveil its in-vivo immune reprogramming technology, a potential cancer treatment game-changer, to global investors.

A landmark European trial for a new genomic test has passed 50% recruitment, promising to tailor breast cancer therapy and improve patient quality of life.

With a promising cancer pipeline, Crescent Biopharma heads to key May conferences to prove its strategy against fierce competition in the bispecific and ADC markets.

Meet the three finalists for the 2026 Extraordinary Healer® Award, recognizing the oncology nurses whose compassion and skill transform patient care.

Creatv Bio will present data at ASCO 2026 on its LifeTracDx® blood test, showcasing its potential to personalize cancer treatment through key pharma partnerships.

A new all-in-one system from Sweden's Multi4 Medical just won EU approval, allowing urologists to treat bladder cancer in minutes without surgery.

With a star-studded new advisory board, Pilatus Biosciences accelerates its attack on cancer's metabolic defenses with its lead drug, PLT012.